What is the Fiscal Year for SELLAS Life Sciences Group?
Date: November 13, 2026
SELLAS Life Sciences Group's current fiscal year starts on January 1, 2026, and ends on December 31, 2026. Their current quarter is Q4, which ends on December 31, 2026.
Current Fiscal Year Overview
Fiscal Year Start
January 1, 2026
Fiscal Year End
December 31, 2026
Current Quarter
Q4
Current Quarter End
December 31, 2026
Quarterly Breakdown
Q1
Jan 1, 2026 – Mar 31, 2026
Q2
Apr 1, 2026 – Jun 30, 2026
Q3
Jul 1, 2026 – Sep 30, 2026
Q4
Oct 1, 2026 – Dec 31, 2026
Company Information
Headquarters
New York, NY
Industry
Biotechnology Research
Stock Symbol
SLS
Description
We are a late-stage clinical biopharmaceutical company focused on developing novel therapies for a broad range of cancer indications. SELLAS’ lead product candidate, galinpepimut-S (GPS), is licensed from Memorial Sloan Kettering Cancer Center and targets the Wilms Tumor 1 (WT1) protein, which is present in an array of tumor types. Our second product candidate, GFH009, is a highly selective small molecule cyclin-dependent kinase 9 (CDK9) inhibitor licensed from GenFleet Therapeutics, which we hold the exclusive rights to for further development and commercialization of the asset across all therapeutic and diagnostic uses outside of greater China. GPS and GFH009 have potential as monotherapies, or in combination with other therapies, to address a broad spectrum of hematologic malignancies and solid tumor indications.
Use Salesmotion for Account Data and Insights
Sales professionals can use Salesmotion to access comprehensive account intelligence and automate their research. Instantly get insights on companies like SELLAS Life Sciences Group and uncover key business information that drives smarter conversations.
Book a demo today to strengthen your sales strategy with powerful data and actionable insights.